These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neural androgen receptor regulation: effects of androgen and antiandrogen. Lu S; Simon NG; Wang Y; Hu S J Neurobiol; 1999 Dec; 41(4):505-12. PubMed ID: 10590174 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer. Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862 [TBL] [Abstract][Full Text] [Related]
4. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473 [TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Bocci G; Danesi R; Marangoni G; Fioravanti A; Boggi U; Esposito I; Fasciani A; Boschi E; Campani D; Bevilacqua G; Mosca F; Del Tacca M Eur J Pharmacol; 2004 Sep; 498(1-3):9-18. PubMed ID: 15363970 [TBL] [Abstract][Full Text] [Related]
6. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015 [TBL] [Abstract][Full Text] [Related]
7. EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer. Schwarz RE; Awasthi N; Konduri S; Cafasso D; Schwarz MA Ann Surg Oncol; 2010 May; 17(5):1442-52. PubMed ID: 20041350 [TBL] [Abstract][Full Text] [Related]
8. Atypical androgen receptor in the human melanoma cell line IIB-MEL-J. Morvillo V; Luthy IA; Bravo AI; Capurro MI; Donaldson M; Quintans C; Calandra RS; Mordoh J Pigment Cell Res; 1995 Jun; 8(3):135-41. PubMed ID: 7567789 [TBL] [Abstract][Full Text] [Related]
9. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008 [TBL] [Abstract][Full Text] [Related]
10. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Naderi A; Chia KM; Liu J Breast Cancer Res; 2011 Apr; 13(2):R36. PubMed ID: 21457548 [TBL] [Abstract][Full Text] [Related]
11. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046 [TBL] [Abstract][Full Text] [Related]
12. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B. Yang Y; Tian W; Yang L; Zhang Q; Zhu M; Liu Y; Li J; Yang L; Liu J; Shen Y; Qi Z J Cancer Res Clin Oncol; 2021 Jan; 147(1):93-103. PubMed ID: 32897433 [TBL] [Abstract][Full Text] [Related]
14. Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Jie X; Lang C; Jian Q; Chaoqun L; Dehua Y; Yi S; Yanping J; Luokun X; Qiuping Z; Hui W; Feili G; Boquan J; Youxin J; Jinquan T Oncogene; 2007 Aug; 26(39):5741-51. PubMed ID: 17369855 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Bruns CJ; Harbison MT; Davis DW; Portera CA; Tsan R; McConkey DJ; Evans DB; Abbruzzese JL; Hicklin DJ; Radinsky R Clin Cancer Res; 2000 May; 6(5):1936-48. PubMed ID: 10815919 [TBL] [Abstract][Full Text] [Related]
16. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594 [TBL] [Abstract][Full Text] [Related]
17. Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. Warriar N; Pagé N; Koutsilieris M; Govindan MV Prostate; 1994 Apr; 24(4):176-86. PubMed ID: 8146066 [TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens. Konduri S; Schwarz RE J Surg Res; 2007 Jun; 140(1):55-66. PubMed ID: 17275032 [TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581 [TBL] [Abstract][Full Text] [Related]
20. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]